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878-1 The PPAR-T Activator Troglitazone, but Not 
Rosiglitazone, Preserves Contractile Function and 
Suppresses Proinflammatory Cytokines in Myocardial 
lschemia and Reperfusion 
Michael W. Gen. Ya Xu, Li Lu, Hasan Ahmad, Daniel Perlov. Carlin S. Long, Gregory G. 
Schwartz. University of Colorado Health Sciences Center, Denver, CO, Denver VA 
MedIcal Center, Denver, CO 
Background: Activation of the nuclear receptor PPARy attenuates expression of pro- 
inflammatory cytokines. PPAR-y is expressed in myocardium and pro-inflammatory 
cytokines may contribute to myocardial dysfunction after ischemitireperfusion (I/R). We 
tested the hypothesis that PPAR-y actwators abrogate expression of cytokines in I/R, and 
preserve LV function. Methods: Non-diabetic pigs were pretreated with rosigfitazone 
@OS. 3 mgfkg/d) or troglitazone (TGZ. 75mgikgfd) for 8 wks. A control group (CON) 
received no pretreatment. Plasma concentrations of ROS and TGZ were similar to clini- 
cal levels. Each pig underwent 90 min low-flow ischemia and 90 min reperfusion. LV 
function was assessed by sonomicrometry. Expression of cytokines and PPAR-y were 
assessed by ribonuclease protection assay. Results: Baseline hemodynamics and 
severity of ischemia were similar in all arouos. After I/R. LV function was similarlv 
depressad In CON (23%*5) and ROS (21%;44). but was significantly greater in TG; 
(44%*5). Cvtokine exoression was also similar between CON and ROS hearts. and sio- ., 
mficantly less in TGZ hearts and non-ischemic myocardium (pc.01, Table). Conclusion: 
The PPAR-yactivator TGZ, but not ROS, preserves LV function and suppresses cyiokine 
expression after myocardial I/R. Different responses to ROS vs. TGZ may reflect expres- 
sion of different PPAR-responswe genes or effects of the non-thiazolidinedione moieties 
of each molecule. 
Group ILil3; 
Non-ischemic, n=18 0.026 
(0.006.0.074) 
I/R CON, n= 17 0.413 
(0.112,0.565) 
I/R ROS, n=lZ 0.275 
(0.245,0.305) 




















Median (25%,75%) normalized to GAPDH; * pc.05 vs non-ischemic 
IO:45 a.m. 
878-2 The Thyroid Hormone Analog, 3,5 Diiodothyropropionic 
Acid (DITPA) Restores Diminished Vascular Beta- 
Adrenergic and Endothelial Mediated Vasorelaxation in 
Heart Failure 
Peter H. Spooner, Steven Goldman, Mohamed A. Gaballa, University of Arizona Sawer 
Heart Center, Tucson, AZ Southern Arizona VA Health Care System, Tucson, AZ 
This study was designed to determine if the thyroid hormone analog 3,5 diiodothyropropi- 
onic acid (DITPA), which is being developed to treat heart failure, affects vascular func- 
tion. This is important because vascular reactivity is altered in heart failure via diminished 
endothelial dependent vasorelaxation and depressed response to beta-adrenergic 
receptor (PAR) stimulation, both systems in which thyroid hormone has been shown to 
have an effect. Myocardial infarction (Ml) was created in adult Sprague Da&y rats by 
ligating the left coronary altery Three weeks after ligation, rats were randomly assigned 
to DITPA or no treatment and sham or MI In a 2x2 factorial design DITPA 375@g/lW gm 
subcutaneous daily for 3 weeks. At ths end of the study. hemodynamics was measured 
and thoracic aortic rings were harvested for vasorelaxation studies. Cultured bovine pul- 
monary endothelial cells were exposed to DITPA for 24 hours and assayed for endothe- 
lial nitric oxide synthase (eNOS) levels. In isolated arterial segments from heart failure 
rats, DITPA enhanced the vasorelaxation response to acetylcholine (45% at 104 acetyl- 
choline, P=O.O38) and to isoproterenol (50% at lOA isoproterenol, P&05). DITPA. at 1 
NM, 10pM and 20pM, increased (P=O.o07) eNOS protem expression in cultured endot- 
helial cells from from a baseline value of 22 09k4.75, to 29.88&61, 52.72516.82 and 
49.09+15.20 lllmg protem. respectively. Thus. after myocardial infarction, DITPA 
enhances endothelial-mediated vasorelaxation through two mechanisms: 1) Increased 
responsiveness to @-AR stimulation and 2) Increased endothellal nitric oxide synthase 
resulting in Increased endothelial dependent vasodilatation and increased NO availability 
in the endothellum. It is possible that the vascular action of DITPA IS medlated through,?- 
AR stimulation, which in turn increases nitric oxide release in the endothelium. 
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878-3 Deletion of Kir6.2 Worsens Diastolic Dysfunction in the 
Stunned Myocardium 
Richard J. Gumina, Christopher E. Kurtz, Peter Bast, Denice Hodgson, Fergus 
O’Coclain, Takashi Miki, Susumu Seine, Andre Terzic. Mayo Clinic and Foundation, 
Rochester, MN 
Background: Sarcolemmal ATP-sensitive potassium (KATP) channels regulate cardiac 
response to stress by supporting calcium homeostasis. However, their role in protection 
from myocardial stunning, a condition associated with dysregulated calcium handling, 
has not been defined. 
Methods: Isolated hearts from wild-type (WT) or Kir6.2.knockout (KO) mice lacking 
Kir6.2. the pore-forming subunit of sarcolemmal KATP channels, were paced at 500 bpm 
and perfused on a Langendodf apparatus for 30 min, then subjected to 10 min of zero- 
flow normothermic &hernia followed by a 30 min-long reperfuslon. Contractile parame- 
ters ware derived from a balloon pressure transducer. Coronay effluents were collected 
for determination of creatine kinase release. ANOVA comparison of means was used for 
statistical analysis. 
Results: On rep&u&n, creatine kinase leakage was negligible and comparable in both 
WT and KO hearts, indicative of non-lethal injury. Characteristic of stunning, WT hearts 
exhiblted a transient reduction in contractile performance measured by rate-pressure 
product and left ventricular end-diastolic pressure (LVEDP: 4.3eO.5 prior to ischemia vs. 
16.4t3.6 and 7.Ok2.1 mmHg at 2.5 and 30 min reperfusion). KO hearts demonstrated a 
more pronounced reduction in RPP accompanied with protracted elevation in LVEDP 
(8.5*1 .O prior to ischemia vs. 34.Oe2.4 and 21.8+ 5.4 mmHg at 2.5 and 30 min reperfu- 
sion). Treatment with the calciumlcalmodulin antagonist W7 abrogated excessive dias- 
tolic dysfunction observed in KO mice, wth a reduction in LVEDP to 21*1 .O and 11.8+0.6 
mmHg at 2.5 and 30 min repetiusion, respectively. 
Conclusion: Knockout of sarcolemmal KATP channels aggravates myocardial stunning 
due to excessive calcium mishandling, resulting in diastolic dysfunction 
11:15 a.m. 
878-4 Apoptosis and DNA Damage Markers in Human Left 
Ventricular Samples Under Controlled lschemia and 
Reperfusion 
Cinzia Perrino, Ciro Indolfi, Gian Giacomo Corbucci, Andrea Ricchi, Giuseppe Donate, 
Enrico Vittorio Awedimento, Massimo Chiariello. Universltv Federico Il. Naoles. Italv. 
Brotzu Hospital, Caghari. Italy 
1 .  
Background Apoptosis has been implicated in in vm animal models of myocardial 
Ischemia-reperfusion and in progressive deterioration of cardiac function. Cardiopulmo- 
nary bypass during cardiac surgery is a controlled human model of myocardial ischemia 
and repelfuslon injury. Methods Human left ventricular samples were taken from 16 
patients undergoing elective valvular surgery (1) before aoriic cross-clamping; (2) 20+2 
minutes (brief ischemia) and (3) 58~5 minutes after cross-clamplng (prolonged 
ischemia); and (4) 21r4 minutes after reconstitution of coronary blood flow (reperfusion). 
Western Blotting were performed in samples from 10 patients to evaluate Mitogen Acti- 
vated Protein Kinases (MAPKs) activation, caspase 3 and 9 activation, ~53 and p21WAF 
protein levels. Left ventncular specimens from 6 patients were subjected to Hematossilin- 
Eosin (HE) and TUNEL staining, Electronic Microscope (EM). Results Brief and pro- 
longed ischemia induced rapid activation of caspase 3 and p531p21wAF. Caspase 3 acti- 
vation was associated to a strong TUNEL signal in nearly 40% of the cells. The staining 
of the same cells with HE did not show morphological changes. EM of the samples 
showed that only in approximately 5% of the cells there ware morphological signs of apo- 
ptosis. More than 80% of the cells showed mitochondrial swelling. Reperfusion was 
associated with significant MAPKs (ERK, Jun, ~38) and mitochondrial caspase 9 activa- 
tion, with still high caspase 3 activation, TUNEL positivity and high p53ip21 WAFle~els. 
HE and ME confirmed the presence of rare changes suggestwe of apoptosis. Finally, we 
found in ischemic and reperfused tissues phosphoylation of Histone H2. which marks 
double strand DNA breaks. Conclusions Myocardial ischemia induces a potent and 
rapid activation of caspase 3, which is potentiated by reperfusion, with mitochondrial 
caspase 9 actwation. Majority of the cells become TUNEL positive during ischemla, 
although morphological signs of apoptosis are present only in 5% of the cells by EM. His- 
tone 2 phosphorylation and ~531~21 activation indicate that ischemia-reperfusion induce 
extensive DNA damage and activate the repair system, apoptosis develops in a minortty 
Of cells 
11:30 a.m. 
878-5 lntracoronary Delivery of Bone Marrow-Derived CD34+ 
Mononuclear Cells Increases Vascular Density in 
Infarcted Myocardium 
Julia N. Sunkomat, Mohamed A. Gaballa, University of Arizona Salver Heari Center, 
Tucson, AZ 
Previous studies demonstrated that necrotic tissue after myocardial infarction can be 
populated with neovessels and cardiomyocytes using intramyocardial injection of specific 
subtypes of adult bone marrow steml progenitor cells. However. this technique may not 
be practical in the clinical setting. In one study. bone marrow stromal cells delivered intra- 
coronary in infarcted myocardium underwent milieu-dependent differentiation into cardi- 
omyocytes and endocardial and capillary endothelial cells. Since bone marrow stromal 
cells contain several subtypes of stem/progenitor cells, it is unclear which subset of bone 
marrow cells differentiate into cardiac cells or vascular endothelial cells. Progenitor 
endothelial cells, CD34’ mononuclear cells (MNCs). were prewously shown to incorpo- 
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rate into neovascularization of the injured tissue. Therefore, this study was designed to 
examine if CD34+ MNCs delivered intracoronary in Infarcted hearts will incorporate in 
neovessels and enhance capillary density within the injured myocardium. Myocardial inf- 
arction was created in inbred Brown Norway (BN) rats. CD34+ MNCs cells were isolated 
from donor BN rats using magnetic beads conjugated to anti-CD34 antibody and the cells 
ware labeled with CFDA SE labeling kit (fluorescence dye). Immediately after infarction, 
1x1@ of the labeled CD34+ MNCs were delivered intracoronary into the infarcted myo- 
cardium. Four weeks after cell delivery, myocardium was sectioned, stained with factor 
VIII. and examined using fluorescence microscopy. Our data show that bone rnarrow- 
derived CD34+ MNCs incorporated into neovessels within the injured myocardium. It also 
ted to increase in capillary density by 18% compared to untreated infarcted rats. In addi- 
tion, a small number of the injected CD34+ MNCs (~0.01%) differentiated into cardiomy- 
ocytes and incorporated within the survived myocardium. Thus, intracoronary delivery of 
bone marrow CD34+ cells may be viable therapeutic option to enhance neovasculariza- 
tion in the injured myocardium after Ml. 
11:45a.m. 
878-6 Platelet Collagen Receptor Glycoprotein VI as a Novel 
Risk Factor for Myocardial Infarction 
Frederick F. Samaha, Michael Varello, Mark L. Kahn, Philadelphia VA Medical Center, 
Philadelphia, PA, University of Pennsylvania, Philadelphia, PA 
Introduction: Following plaque rupture, the response of circulating platelets determines 
whether thrombotic occlusion with myocardial infarction (Ml) or plaque stabilization 
occur. The first activating signal to which platelets are exposed following vessel injury is 
collagen. The expression level of platelet collagen receptor glycoprotein (GP) VI is pro- 
portional to the strength of collagen signaling responses in cell lines, and polymorphisms 
associated with elevated platelet collagen receptor a2bl expression have been associ- 
ated with an increased risk of stroke. We used a novel anti-GPVI m~n~clonal antibody, 
and an antia2bl antibody to assess whether collagen receptor expression levels are risk 
factors for MI. 
Methods: We used flow cytometry with FITC-conjugated monoclonal antibody to assess 
receptor expression level in 44 subjects with and 56 subjects without a history of Ml. 
Results: GPVI receptor density was significantly higher in subjects with history of Ml 
(2891 +/- 1482 molecules of equivalent fluorescence) (MEF) versus those with no history 
of Ml (2348 +/- 1231 MEF) (p=O.O48), though less so after correction for baseline tradi- 
tional Ml risk factors (p=O.O57). However, subjects with Ml prior to age 50 had incremen- 
tally higher GPVI levels (3260 +/- 1740 MEF) compared to those with no history of Ml 
(p=O.O26), independently of baseline traditional risk factors (p=O.O43). There was no 
association between a2bl receptor density and Ml (p=O.21) or MI under age 50 (p=O.27). 
Conclusion: GPVI expression level is a novel independent risk factor for myocardial inf- 
arction, especially in younger patients. These results suggest that elevated GPVI levels 
may result in more rapid and complete platelet activation following plaque rupture, 
increasing the likelihood of thrombotic occlusion and myocardial infarction. 
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881 FO-2 Clinical Evidence for Benefit of lntracoronary 
Progenitor Cell Therapy on Post-Infarction Remodeling: 
Results of the TOPCARE-AMI Trial 
Volker Schachinqer, Birgit Assmus, Ralf Lehmann, Claudius Teupe. Martina Britten, 
Natascha Doebert, Hans Martin. Stefanie Dimmeler, Andreas M. Zeiher, J. W. Goethe 
University, Frankfurt, Germany 
Background: Experimentally, blood or bone-marrow derived prognitor cells were shown 
to contribute to regeneration and neovascularization of ischemic tissue. In this pilot 
study, we tested the safety and feasibility of autologous progenitor cell transplantation 
after acute myocardial infarction (AMI). 
Methods: We randomly allocated 20 patients with repelfused AMI to receive intracoro- 
nary infusion of either bone marrow-derived (w9) or circulationg blood-derived progeni- 
tor cells (n=l I) into the infarct artery 4.3&l .5 days after AMI. Left ventricular angiography 
(LVA), coronary flow reserve (i.c. adenosine), echocardiography and FDG-PET were 
performed at the time of progenitor cell infusion and after 4 months. Results: Transplan- 
tation of progenitor cells was associated with a significant increase in global left ventricu- 
lar ejection fraction by LVA from 52t9.6 to 60+8.6 % (p=O.O03) and a reduction of 
endsystolic left ventricular volumes (56t20 to 42*14 ml; p=O.Ol). Echocardiography 
revealed a profound enhancement of regional contractile function in the infarct zone 
(decrease in wall motion score index from 1.4kO.2 to 1.2*0.2; p-zO.001) accompanied by 
a significant increase in myocardial viability detected by quantitative FDG-PET analysis 
(54il3 to 63+1 I; pcO.01). At baseline, CFR was significantly impaired in the infarct 
artery compared to the reference vessel (2.4iO.55 vs. 3.450.80, p<O.Ol). After 4 months, 
CFR was significantly improved in the infarct artery and did no longer differ from CFR in 
the reference vessel (4.2~1.2 vs. 4.5kO.8, p=n.s.). For all parameters assessed, there 
were no differences between patients treated with bone marrow-derived compared to cir- 
culating blood-derived cells. No signs of an inflammatory response or malignant arrhyth- 
mias were observed. Conclusions: In patients with acute myocardral infarction 
undergoing acute revascularization. intracoronary infusion of autologous progenitor cells 
appears to be feasable and safe. Furthermore, compared to historical data, this pilot 
study suggests a beneficial effect of progenitor cells on coronary blood flow regulation 
and post infarction remodeling processes. 
1l:OO a.m. 
881 FO-3 Protection Against Reperfusion Injury With ITF-1697 in 
Acute Myocardial Infarction: The PARI-MI Trial 
Maurfts T. Dirksen, Arnoud W. van ‘t Hof. G. Guagliumi. H. R. Michels, M. L. Sirnoons, L. 
Tavazzi, G. J. Laarman. for the PARI-MI Investigators, Onze Lieve Vrouwe Gasthuis. 
Amsterdam, The Netherlands, Erasmus Medical Centre, Rotterdam, The Netherlands 
Background: ITF-1697 is a C-reactive protein-derived tetrapeptide that increases myo- 
cardial perfusion and reduces infarct size in various experimental animal models of 
ischemia and ischemia-reperfusion. ITF-1697 is thought to reduce reperfusion injury by 
preservation of the integrity of microcirculation and inhibition of polymorphonuclear neu- 
trophil and platelet adhesion to the endothelium. The study was performed to assess 
safety, efficacy and clinical outcome of prolonged i.v. infusion of ITF-1697 in 4 dosages 
(0.1,0.5, 1 .O and 2.0 “gikglmin), in patients wth an acute myocardial infarction (AMI) eli- 
gible for primary percutaneous angioplasty (PCI). 
Methods The design of the study was randomized, double blind, multicentre, placebo- 
controlled and dose finding. Patients with AMI were enrolled within 12 hours after onset 
of symptoms, with ST-segment deviation more than 0.2 mV in two or more contiguous 
leads and sum of ST elevation more than IO mm. I.v. infusion was started before proce- 
dure up to 24 hours. Safety was evaluated by incidence of death and serious adverse 
events (SAEs). Efficacy was measured by improved perfusion (TIMI flow, TIMI frame 
count, blush grade, ST-segment resolution) and reduced myocardial damage (enzy- 
matic). Clinical outcome was assessed by incidence of death, recurrent AMI, recurrent 
ischemia and SAEs. 
Results: 402 patients were enrolled. After interim analysis the study was continued with 
0.1 and 1.0 ITF-1697 @kgfmin. Interim and final analysis did not raise any safety con- 
cerns. Post-procedure perfusion was similar for placebo, 0.1 and 1.0. TIMI flow grade.3 
was seen in 82.2%, 84.4% (ns) and 87.5% (ns) respectively, blush grade 3 in 32.5%, 
16.7% (ns) and 18.5% (ns) respectively. No differences were shown in the corrected 
TIMI frame count. ST-segment resolution 1 and 3 hours after PCI was equal. Enzymatic 
infarct size was not different between the three groups. At discharge and after 30 days 
follow-up no significant differences between placebo and one of the dosages could be 
detected in clinical outcome. 
Conclusion: Although well tolerated, ITF-1697 failed to show improvement of perfusion 
or reduction of myocardial damage after primary PCI in patients with AMI. 
11:15 a.m. 
881 FO-4 Efficacy of a Novel P-Selectin Antagonist, rPSGL-lg for 
Reperfusion Therapy in Acute Myocardial Infarction: 
The RAPSODY Trial 
Jean-Francois Tanauay, Mitchell W. Krucoff, Raymond J. Gibbons, Eduardo Chavez, 
Alvaro Sosa Liprandi, Victor Molina-Viamonte, Philip E. Aylward, Jose Luis Lopez- 
Sendon, D. Scott Holloway, Kathy Shields, Jenny S. Yu, Evan Loh, Kenneth W. Baran. 
Vasanth K. Bethala. Alec Vahanian, Harvey D. White, for the RAPSODY Investigators, 
Montreal Heart Institute, Montreal, Canada, Wyeth Research, Collegeville, PA 
Background: Platelet-leukocyte interactions, mediated by P-selectin, have been impli- 
cated in thrombosis. A recombinant antagonist (rPSGL-lg) in conjunction with throm- 
bolytic therapy (tPA) has been demonstrated in pre-clinical studies to accelerate 
thrombolysis, reduce reperfusion injury. and reduce reocclusion. This multicenter. ran- 
domized trial, dose-rangrng study was performed using rPSGL-Ig in combination with tPA 
in patients with AMI to determine if P-selectin antagonism will improve ST segment reso- 
lution and infarct size. 
Methods: 598 patients who presented with ST elevation and chest pain ~6 hours, and 
who were eligible for thrombolytic therapy were included. All patients received tPA. Three 
(3) doses of rPSGL-Ig were compared with placebo. Continuous IPlead ST-monitoring 
was performed for the first 24 hours. Infarct srze and ejection fraction were determined by 
sestamibi-SPECT on day 7 and MUGA on day 30. Clinical outcome was monitored for 6 
months. 
Results: No differences were observed in baseline charactenstics (age, sex, diabetes, 
Ml location, time to tPA). 
rPSGL-Ig Dose 0 5 25 75 p-Value’ 
mg mg mg mg 
N 144 148 151 155 
Time to ST Resolution (hr)#@ 2.0 2.0 2.2 2.5 0.006 
InfarctSizeanterior (%LV)# 26 35 37 26 NS 
Infarct Size other (%LV)# 13 9 16 13 NS 
Ejection Fraction (%)#a 52 50 51 51 NS 
Death/Ml Day 30 (%) 7 2 5 7 NS 
Death/MI Month 6 (%) 8 11 10 IO NS 
Stroke (%) 3.5 2.0 2.0 1.3 NS 
